Document is current
Any future updates will be listed below
-
Authors
Gehrung, Marcel https://orcid.org/0000-0001-6915-9552
Crispin-Ortuzar, Mireia https://orcid.org/0000-0002-4351-3709
Berman, Adam G.
O’Donovan, Maria
Fitzgerald, Rebecca C.
Markowetz, Florian https://orcid.org/0000-0002-2784-5308
- License Information
-
More Information
Article History
Received: 24 April 2020
Accepted: 17 February 2021
First Online: 15 April 2021
Competing interests
: The Cytosponge device technology and the associated TFF3 biomarker are licensed to Covidien GI solutions (now owned by Medtronic) by the Medical Research Council. M.G., M.C.O. and F.M. are named inventors on a patent pertaining to technology applied in this work. R.C.F. and M.O. are named inventors on patents pertaining to the Cytosponge and associated technology. M.G., M.O. and R.C.F. are shareholders of Cyted Ltd., a company working on early detection technology.
